Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.